Blood Res 2021; 56(S1):
Published online April 30, 2021
https://doi.org/10.5045/br.2021.2020320
© The Korean Society of Hematology
Correspondence to : Jun Ho Yi, M.D., Ph.D.
Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
E-mail: xuno@daum.net
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Despite substantially improved survival with rituximab-based treatment regimens, there is an unmet medical need for better treatments of B-cell lymphoma, particularly for patients with relapsed or refractory disease. Retreatment with rituximab exerts a limited effect in these patients, and platinum-based salvage treatment followed by autologous stem cell transplantation remains the only curative option. Recent strategies have focused on targeting novel B-cell surface markers, inhibiting B-cell receptor signaling, and enhancing the cytotoxicity of effector cells. The current article will review the recent progress in immunochemotherapy targeting other than CD20 for B-cell lymphomas.
Keywords B-cell lymphoma, CD19, CD22, CD79b
Blood Res 2021; 56(S1): S1-S4
Published online April 30, 2021 https://doi.org/10.5045/br.2021.2020320
Copyright © The Korean Society of Hematology.
Jun Ho Yi
Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea
Correspondence to:Jun Ho Yi, M.D., Ph.D.
Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
E-mail: xuno@daum.net
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Despite substantially improved survival with rituximab-based treatment regimens, there is an unmet medical need for better treatments of B-cell lymphoma, particularly for patients with relapsed or refractory disease. Retreatment with rituximab exerts a limited effect in these patients, and platinum-based salvage treatment followed by autologous stem cell transplantation remains the only curative option. Recent strategies have focused on targeting novel B-cell surface markers, inhibiting B-cell receptor signaling, and enhancing the cytotoxicity of effector cells. The current article will review the recent progress in immunochemotherapy targeting other than CD20 for B-cell lymphomas.
Keywords: B-cell lymphoma, CD19, CD22, CD79b
Mesut Göçer, Erdal Kurtoğlu
Blood Res 2020; 55(4): 206-212Masashi Ohe, and Satoshi Hashino
Korean J Hematol 2011; 46(3): 203-206Deok Hwan Yang, Je Jung Lee, Yeo Kyeoung Kim, Jeong Rae Byun, Sang Hee Cho, Ik Joo Chung, Hyeoung Joon Kim, Jong Gwang Kim, Dong Hwan Kim, Sang Kyung Sohn, Won Sup Lee, Young Rok Do, Hong Suk Song, Joon Seong Park, Hugh Chul Kim
Korean J Hematol 2004; 39(2): 59-65